ZVRA · US market
ZEVRA THERAPEUTICS INC COM NEW
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$604.53mFinancials dated 30 June 2026Price dated 1 October 2026
Core valuation
Calculation inputs
- Trailing earnings
- US$57.49m
- Latest-quarter run-rate earnings
- US$33.57m
- Latest fiscal-year earnings
- US$77.59m
- Trailing revenue
- US$136.07m
- Latest-quarter run-rate revenue
- US$158.65m
- Latest fiscal-year revenue
- US$106.47m
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- XPH · State Street SPDR S&P Pharmaceuticals ETF0.95% weight · Holdings dated 21 August 2026
- PTH · Invesco Dorsey Wright Healthcare Momentum ETF0.74% weight · Holdings dated 19 August 2026
- RPMIX · Royce Small-Cap Fund Institutional Class0.18% weight · Holdings dated 30 June 2026
- JTUAX · JPMorgan U.S. Small Company Fund Class A0.16% weight · Holdings dated 30 June 2026
- IWC · iShares Micro-Cap ETF0.16% weight · Holdings dated 21 August 2026
- WSCJX · Allspring Disciplined Small Cap Fund Class R60.16% weight · Holdings dated 30 June 2026
- VFMF · Vanguard U.S. Multifactor ETF0.15% weight · Holdings dated 15 September 2026
- AFSM · First Trust Active Factor Small Cap ETF0.11% weight · Holdings dated 31 May 2026
- EES · WisdomTree U.S. SmallCap Fund0.10% weight · Holdings dated 30 June 2026
- QSML · WisdomTree U.S. SmallCap Quality Growth Fund0.08% weight · Holdings dated 30 June 2026
Sources and limitations
Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 30 June 2026. Informational research, not investment advice.